Gracell Biotechnologies Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Gracell Biotechnologies Inc (GRCL) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
API endpoints for this dataset
Gracell Biotechnologies Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Gracell Biotechnologies Inc | - | - | - | Yes |
| High-Confidence Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
GRCL Stock Performance relative to its Competitors
GRCL Stock Performance relative to High-Confidence Competitors
Gracell Biotechnologies Inc's Competitors Named by the Company
Competitive relationships identified from Gracell Biotechnologies Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Legend Biotech Corporation | Company report | 85% |
| Gilead Sciences, Inc. | Company report | 85% |
| Poseida Therapeutics, Inc. | Company report | 85% |
| Celgene Corporation | Company report | 85% |
| Nanjing Legend Biotech | Company report | 85% |
| Allogene, Inc. | Company report | 85% |
| Juno Therapeutics, Inc. | Company report | 85% |
| Celyad Oncology AG | Company report | 85% |
| Novartis AG | Company report | 85% |
| bluebird Bio, Inc. | Company report | 85% |
| Kite Pharma, Inc. | Company report | 85% |
Company report basis, confidence, active dates and source counts for Gracell Biotechnologies Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from Gracell Biotechnologies Inc reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.